Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy

Stacy Stephenson, Weilian Yang, Phillip J. Stevens, Werner Tjarks, Rolf F. Barth, Robert J. Lee

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: The folate receptor is amplified in a variety of human tumors including over 90% of ovarian carcinoma. FR-targeted liposomes have previously been used by us to selectively deliver entrapped boron-containing compounds to tumor cells for neutron capture therapy (NCT). In the present study we have evaluated the delivery of Na3(B20H17NH 3), which has been loaded into FR-targeted liposomes, in mice bearing xenograft implants of FR (+) KB subcutaneous tumor. Materials and Methods: Na3(B20H17NH3) was passively entrapped into FR-targeted liposomes, which were administered intravenously into nude mice bearing s.c. implants of the FR(+) human oral carcinoma KB cell line. Normal and tumor boron content was measured by direct current plasma-atomic emission spectroscopy. Results: Mice that received FR-targeted liposomes containing boron showed the highest tumor boron levels at 24 hours (6.1 μg/g) and tumor/blood boron ratios continued to rise for up to 120 hours. Conclusion: Boron delivery via FR-targeted liposomes is feasible and potentially can improve tumor uptake compared to non-targeted liposomes, and may improve cellular and subcellular localization.

Original languageEnglish (US)
Pages (from-to)3341-3345
Number of pages5
JournalAnticancer research
Volume23
Issue number4
StatePublished - Jul 1 2003

Fingerprint

Boron Neutron Capture Therapy
Folic Acid
Liposomes
Boron
Neoplasms
Neutron Capture Therapy
Boron Compounds
Carcinoma
KB Cells
Heterografts
Nude Mice
Spectrum Analysis
Cell Line

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Stephenson, S., Yang, W., Stevens, P. J., Tjarks, W., Barth, R. F., & Lee, R. J. (2003). Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. Anticancer research, 23(4), 3341-3345.

Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. / Stephenson, Stacy; Yang, Weilian; Stevens, Phillip J.; Tjarks, Werner; Barth, Rolf F.; Lee, Robert J.

In: Anticancer research, Vol. 23, No. 4, 01.07.2003, p. 3341-3345.

Research output: Contribution to journalArticle

Stephenson, S, Yang, W, Stevens, PJ, Tjarks, W, Barth, RF & Lee, RJ 2003, 'Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy', Anticancer research, vol. 23, no. 4, pp. 3341-3345.
Stephenson, Stacy ; Yang, Weilian ; Stevens, Phillip J. ; Tjarks, Werner ; Barth, Rolf F. ; Lee, Robert J. / Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. In: Anticancer research. 2003 ; Vol. 23, No. 4. pp. 3341-3345.
@article{d61e815daebd4b04ae40edeb6ee75d9d,
title = "Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy",
abstract = "Background: The folate receptor is amplified in a variety of human tumors including over 90{\%} of ovarian carcinoma. FR-targeted liposomes have previously been used by us to selectively deliver entrapped boron-containing compounds to tumor cells for neutron capture therapy (NCT). In the present study we have evaluated the delivery of Na3(B20H17NH 3), which has been loaded into FR-targeted liposomes, in mice bearing xenograft implants of FR (+) KB subcutaneous tumor. Materials and Methods: Na3(B20H17NH3) was passively entrapped into FR-targeted liposomes, which were administered intravenously into nude mice bearing s.c. implants of the FR(+) human oral carcinoma KB cell line. Normal and tumor boron content was measured by direct current plasma-atomic emission spectroscopy. Results: Mice that received FR-targeted liposomes containing boron showed the highest tumor boron levels at 24 hours (6.1 μg/g) and tumor/blood boron ratios continued to rise for up to 120 hours. Conclusion: Boron delivery via FR-targeted liposomes is feasible and potentially can improve tumor uptake compared to non-targeted liposomes, and may improve cellular and subcellular localization.",
author = "Stacy Stephenson and Weilian Yang and Stevens, {Phillip J.} and Werner Tjarks and Barth, {Rolf F.} and Lee, {Robert J.}",
year = "2003",
month = "7",
day = "1",
language = "English (US)",
volume = "23",
pages = "3341--3345",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy

AU - Stephenson, Stacy

AU - Yang, Weilian

AU - Stevens, Phillip J.

AU - Tjarks, Werner

AU - Barth, Rolf F.

AU - Lee, Robert J.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Background: The folate receptor is amplified in a variety of human tumors including over 90% of ovarian carcinoma. FR-targeted liposomes have previously been used by us to selectively deliver entrapped boron-containing compounds to tumor cells for neutron capture therapy (NCT). In the present study we have evaluated the delivery of Na3(B20H17NH 3), which has been loaded into FR-targeted liposomes, in mice bearing xenograft implants of FR (+) KB subcutaneous tumor. Materials and Methods: Na3(B20H17NH3) was passively entrapped into FR-targeted liposomes, which were administered intravenously into nude mice bearing s.c. implants of the FR(+) human oral carcinoma KB cell line. Normal and tumor boron content was measured by direct current plasma-atomic emission spectroscopy. Results: Mice that received FR-targeted liposomes containing boron showed the highest tumor boron levels at 24 hours (6.1 μg/g) and tumor/blood boron ratios continued to rise for up to 120 hours. Conclusion: Boron delivery via FR-targeted liposomes is feasible and potentially can improve tumor uptake compared to non-targeted liposomes, and may improve cellular and subcellular localization.

AB - Background: The folate receptor is amplified in a variety of human tumors including over 90% of ovarian carcinoma. FR-targeted liposomes have previously been used by us to selectively deliver entrapped boron-containing compounds to tumor cells for neutron capture therapy (NCT). In the present study we have evaluated the delivery of Na3(B20H17NH 3), which has been loaded into FR-targeted liposomes, in mice bearing xenograft implants of FR (+) KB subcutaneous tumor. Materials and Methods: Na3(B20H17NH3) was passively entrapped into FR-targeted liposomes, which were administered intravenously into nude mice bearing s.c. implants of the FR(+) human oral carcinoma KB cell line. Normal and tumor boron content was measured by direct current plasma-atomic emission spectroscopy. Results: Mice that received FR-targeted liposomes containing boron showed the highest tumor boron levels at 24 hours (6.1 μg/g) and tumor/blood boron ratios continued to rise for up to 120 hours. Conclusion: Boron delivery via FR-targeted liposomes is feasible and potentially can improve tumor uptake compared to non-targeted liposomes, and may improve cellular and subcellular localization.

UR - http://www.scopus.com/inward/record.url?scp=0042530136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042530136&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 3341

EP - 3345

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -